Edit |   |
---|---|
Antigenic Specificity | APP Abeta40, Human (Ponezumab biosimilar) |
Clone | Ponezumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG2 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | ELISA, IP, FCM, FuncS, Neut |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human APP Abeta40 Recombinant Antibody. Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease. Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial. Detailed reports have to be released. |
Immunogen | n/a |
Other Names | Anti-APP Abeta40 Recombinant Antibody, Research Grade Ponezumab, Anti-Human APP Abeta40 Recombinant Antibody, PF-04360365, RN-1219, clone 9TL, Antibody Drug Analogues, Monoclonal Antibody, YR1248, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1178862-65-1 |
Catalog # | YR1248 |
Price | please inquire |
Order / More Info | APP Abeta40, Human (Ponezumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |